Every day over 22,000 people around the world die due to neoplastic diseases. In Europe in 2012, over 400 K of new cases of prostate cancer were diagnosed with over 92 K deaths. Globally almost 110 K new patients were diagnosed in 2012 and almost 31 K died because of it.

Current therapeutic methods are mainly invasive and can permanently damage the prostate’s functionalities. Lower risks and more directed doses of radiation help to lower progress of disease and reach even metastatic areas.

The aim of the company is to create products capable of higher precision and less side effects in cancer imaging and radiotherapy. NanoThea is able to achieve this by closing well known radioisotopes in our polysaccharide nanoparticles and targeting system. The unique features of our product are:
– the nanoparticles’ structure allows high tumor/blood ratio, increasing safety of the radiotherapy
– appropriate engineered linker for targeting molecule
– radiochemical stability
– lack of toxicity of the carrier – materials approved by FDA for safety (dextran)
– radiolabeling in situ in the hospital, before administration


As Henry Ford once wished to
build a car for everybody

our mission is to give every patient
chance for a reliable and precise diagnostics and early cancer detection.


To create nanoparticle that reaches even first few tumor cells
and join forces to accelerate it to every hospital.

About Us

NanoThea is developing an innovative radiopharmaceutical for PET diagnosis and treatment of patients with metastatic tumors that are resistant to current used therapies. Our main goal is to create a precise tool for prostate cancer PET diagnostics and focal brachytherapy.
The innovative approach to the radioisotope carrier focuses on maximizing availability of nanoparticles for cancer cells spread within the organism. To maximize the efficiency our products are characterized with higher tumor/blood ratio when compared to current solutions which increases safety and efficacy of solution.
In the future, the company wants to combine diagnostic methods – using PET/MR with treatment. NanoThea will use a molecule that can bind with various types of radioisotopes/elements using our nanoparticle for different diagnostic methods: e.g. using radioactive Ga or Cu for PET diagnostics and Gd for MRI and Lu or Y for treatment. The next and final step is surface modification, not only for adjustment of zeta potential but also for precise targeting with oligopeptides or antimetabolites.
Due to very invasive methods of treatment nowadays – there is a possibility of adaptive shortcuts for clinical pathway. We intend to combine the procedure for both applications, thus minimizing time and costs dedicated for the trials.

Our story

Since 2012 we started to work on nanotechnology for cancer treatment and diagnosis.
In BioMedical Engineering Laboratory, established by prof. Tomasz Ciach at Warsaw University of Technology, we developed novel nanoparticles for cancer treatment using chemotherapeutics.

As a step forward after our first adventure with encapsulating drugs inside nanoparticles we decided to create nanoparticles for cancer diagnostics. We focused our research on two methods: fluorescence and radioisotopes. With combining these two methods we are able to track on-line the fate of nanoparticle in the organism. Thanks to radioisotopes even small signal from few cancer cells is visible on the PET scan. Our ideas and attitude attracted attention of two VC companies. In September 2015, together with Giza Polish Ventures and StartVenture@Poland we founded NanoThea to commercialize the innovative tool for cancer diagnostics. Now we are working to go global with our idea.

Our team

For almost 30 years he has been involved in research and consulting in the health market. His professional experience includes many years of managing the Polish branch and the Central European region at IMS Health (IQVIA) and managing research and consulting companies Azyx, Sequence HC Partners and PEX PharmaSequence. He is the author of a number of presentations at many conferences in Poland and abroad as well as publications in the general and professional press on the Polish health market, and the drug market in particular.

Stefan Bogusławski
Member of Supervisory Board

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Piotr Mierzejewski
Member of Supervisory Board

PhD hab., Associated Professor at Warsaw University of Technology, specialist in the field of Biomedical Engineering, inventor of three products introduced to the market, author of more than 20 patents and patent applications.

Tomasz Ciach
Founder, Member of Supervisory Board


We present improved tumor targeting delivery system, carrying diagnostic radioisotope for PET or SPECT detectors.

Our technology  key features:

  • Based on safe polymer nanocarrier
  • Nanoparticles accumulate inside tumor tissue due to enhanced permeation and retention through the leaky blood vessels
  • Confirmed non-toxicity and biocompatibility
  • Universal – for various cancer cell types
  • Theranostic approach – nanoparticles for diagnostics, also with potential therapeutic use
  • Precise diagnostics exploiting radioisotopes

More details about Technology will be available immediately after patent submission.


Giza Polish Ventures

BioMedical Engineering Laboratory

StartUp Hub Poland

National Centre for Research and Development

Start Venture@Poland

Bridge Alfa

Warsaw university of technology

Contact Us

info [at a domain of] nanothea.com
NanoThea S.A
Rakowiecka 36
02-532 Warszawa, Poland

TAX ID (NIP): PL7010520710
District Court for the Capital City of Warsaw, XIII Commercial Division of the National Court Register No. (KRS) 584108.
Share capital of PLN 282 944,00 paid in full.

I am text block. Click edit button to change this text.


Project co-financed by the European Regional Development Fund under the Operational Programme Innovative Economy.


Project co-financed by the National Centre for Research and Development under the Smart Growth Operational Programme 2014-2020.


Project co-financed by the the European Regional Development Fund under the Mazovian Regional Operational Program for the years 2014-2020.